스테로이드 투여 초기에 발생하는 중증근무력증 증상 악화의 임상적 예측 인자
Clinical Predictors of Steroid-induced Initial Exacerbation in Myasthenia Gravis
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background: The use of prednisone in the treatment of myasthenia gravis (MG) has been required circumspection because of its tendency to produce exacerbations of weakness in the early stages of treatment, often requiring critical management. However, factors influencing the exacerbation has not been defined well. The purpose of this study was to evaluate the clinical factors predicting the exacerbation by prednisone in the early stage of treatment in MG. Methods: Fifty five patients, first-ever prescribed high dose prednsone (40-80 mg) during hospitalization in Samsung Medical Center were included. Prednisone induced exacerbation was defined as significant exacerbation of objective neurologic signs of MG within 4 weeks after prednisone addition by utilizing Myasthnia gravis Severity Scale (MSS). We investigate the differences between the exacerbated and nonexacerbated groups in the clinical, laboratory and electrophysiological features. Results: Twenty three patients (42%) experienced definite exacerbation after prednisone treatment. Old age, presence of bulbar symptom, and severe neurologic finding reflected by MSS score were significant predictors of prednisone induced exacerbation in multivariate logistic regression analysis. Higher prednisone dosage per body weight (Kg) was neither a significant predictor of exacerbation nor related with the early improvement in bivariate correlation. Conclusions: Prednisone induced exacerbation in MG is a frequent challenging problem to clinician. Clinicans should keep in mind the possibility of exacerbation of MG when prescribing prednisone especially, to old, bulbar dominant, severe and disable myasthenic patients.
참고문헌 (20)
- "Therapy in neuromuscular disease", 19, pp.205~215 (2001)
- "Myasthenia gravis:effect of treatment with anterior pituitary extract", 104, pp.2065~2066 (1935)
- "Effects of adrenocorticotropic hormone on neuromuscular function in patients with myasthenia gravis", 71, pp.432~435 (1949)
- "Effects of adrenocorticotropic hormone on neuromuscular function in patients with myasthenia gravis", 28, pp.1228~1235 (1949)
- "A clinical study on crisis in myasthenia gravis", 2, pp.29~39 (1984)
- "Treatment of myasthenia gravis with prednisone", 1, pp.765~767 (1972)
- "Corticosteroids in management of severe Effectiveness and comparison with corticotropin therapy", pp.603~610
- "Quantitative assessment and outcome measures in neuromuscular disease Neuromuscular disorders in clinical practice", pp.309~343 (2002), Butterworth-Heinemann
- "Treatment of autoimmune myasthenia gravis", 61, pp.1652~1661 (2003)
- "Gradually increasing doses of pred-nisone in myasthenia gravis.Reducing the hazards of treatment", 290, pp.81~84 (1974)
- "Myasthenia gravis in patients with thymoma with particular reference to onset after thymectomy", pp.411~433 (1978)
- "The place of corticotropin in the treatment of myasthenia gravis", 52, pp.806~818 (1960)
- "Immune regulation of experimental myasthenia", 43, pp.634~643 (1980)
- "Myasthenia gravis", 330, pp.1797~1810 (1994)
- "Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients", 54, pp.406~411 (1991)
- "Steroid treatment for myasthenia gravis:steroids have an important role", 25, pp.117~121 (2002)
- "Myasthenia gravis.An analysis of 295 cases", 42 suppl 23, pp.1~27 (1966)
- "Preliminary results of a double-blind,randomized,placebo-controlled trial of cyclosporine in myasthenia gravis", 316, pp.719~724 (1987)
- "Benefit from alternate-day prednisone in myasthenia gravis", 286, pp.17~20 (1972)
- "Myasthenia gravis and myasthenic syndromes treated with prednisone", 47, pp.464~474 (1971)